Navigation Links
Gen-Probe to Webcast Three Upcoming Investor Presentations
Date:2/24/2011

SAN DIEGO, Feb. 24, 2011 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at three upcoming investor conferences:

  • RBC Capital Markets' Healthcare Conference in New York at 10 a.m. Eastern Time (ET) on March 2.  The Company also will participate in a panel discussion entitled The Future of Molecular Testing at 3:35 p.m. ET the same day.
  • Cowen and Company's 31st Annual Healthcare Conference in Boston at 10:15 a.m. ET on March 9.
  • Barclays Capital's 2011 Global Healthcare Conference in Miami at 3:15 p.m. ET on March 16.

  • The presentations and the panel discussion will be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com.  The webcasts will be available for 30 days following the events.

    About Gen-ProbeGen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

    Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-K, and all subsequent periodic filings.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.Contact:Paula IzidoroInvestor Relations858-410-8904
    '/>"/>

    SOURCE Gen-Probe Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
    2. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
    3. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
    4. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
    5. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
    6. Gen-Probe to Webcast Two Upcoming Investor Presentations
    7. Neogen Acquires Gen-Probes BioKits Food Safety Business
    8. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
    9. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
    10. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
    11. Gen-Probe to Webcast Two Upcoming Investor Presentations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
    (Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
    (Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
    Breaking Medicine Technology:
    (Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... years of experience in leading technology and human resources operations for health care, ... Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Dr. LeRoy Perry’s recently authored whitepaper, ... mobile devices on the billions of users, hundreds of millions of whom are coming ... life threatening, the frequent and common action of looking down at hand-held technology devices ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel Film Studios ... , "This new layered style transition tool will keep a consistent flow to your ... Pixel Film Studios. , TranSweep is an all new layered style transition tool ...
    (Date:5/26/2016)... ON (PRWEB) , ... May 26, 2016 , ... ... Organization, is proud to announce that it has successfully completed another Health Canada ... Branch Inspectorate of Health Canada. The rating resulted from a Good Manufacturing Practices ...
    (Date:5/26/2016)... ... May 26, 2016 , ... ... weekend to host their second pop-up shop for three consecutive weekends. The pop-up ... to the Santa Barbara community, a community full of women who appreciate the ...
    Breaking Medicine News(10 mins):